Mediwave Showcases AI and AR Emergency Response Technology at EMS World 2024
LAS VEGAS, Sept. 19, 2024 /PRNewswire/ -- Mediwave, a leader in emergency response solutions for prehospital care, made a significant impact at EMS World 2024, the largest Emergency Medical Services (EMS) convention in the United States, held at the Las Vegas Convention Center. Earlier this year, Mediwave launched the world's first end-to-end emergency response suite powered by Artificial...
Breakthrough Research Presented in Scientific Reports Demonstrates How Gene-Edited Microbes Offer a New Source of Nitrogen to Farmers
Findings are the first, peer-reviewed evidence of gene-edited microbes supplying a material proportion of corn farmers' nitrogen in commercial production BERKELEY, Calif., Nov. 14, 2024 /PRNewswire/ -- Peer-reviewed research published today in Scientific Reports describes a new technology that could revolutionize a century-old approach to providing nitrogen to crops. The study, a collaboration of researchers from the University of Wisconsin-Madison, Purdue...
PSB Academy Unveils Third City Campus in Singapore, Plans to Advance Industry-Relevant Education
Located at the iconic The Cathay building, PSB Academy's (PSBA) third campus spans 28,000 sq ft and features state-of-the-art facilities designed to enhance the learning experience, particularly for distance-learning students. The Cathay Campus will offer industry-relevant programmes in collaboration with Coventry University, ensuring that students gain practical skills for real-world applications. The...
Acepodia Announces FDA Clearance of IND Application for ACE1831, an Anti-CD20 Armed Allogeneic gamma delta T-cell Therapy Candidate to Treat Patients with non-Hodgkin’s Lymphoma
ACE1831 is a potential antibody‑armed allogeneic gamma delta T cell therapy developed using Acepodia's unique antibody-cell conjugation (ACC) technology as an optimized T cell engager platform to treat patients with non-Hodgkin's lymphoma ALAMEDA, Calif. and TAIPEI, Taiwan, June 20, 2022 /PRNewswire/ -- Acepodia, a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) platform...
AASLD 2022 | Ascentage Pharma to Announce Results from First-in-Human Study of IAP Antagonist APG-1387 in an Oral Report at the AASLD Annual Meeting
SUZHOU, China and ROCKVILLE, Md., Oct. 20, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it will release results from the Phase I first-in-human study of APG-1387, the company's investigational inhibitor of apoptosis...
Transcenta Presented Two Scientific Posters at SITC 2022 Annual Meeting
SUZHOU, China, Nov. 11, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it has presented two scientific posters at the 37th Society for Immunotherapy of Cancer's (SITC) Annual Meeting in Boston, MA, November 8-12, 2022. One related to...
WuXi Vaccines Establishes New Vaccines CDMO Facility in China
SUZHOU, China, Nov. 15, 2022 /PRNewswire/ -- WuXi Vaccines, a leading global Contract Development and Manufacturing Organization (CDMO), announced that it has entered into an agreement with Harbour BioMed under which Harbour BioMed's manufacturing facility in Suzhou will be transferred to WuXi Vaccines. The 8,500-square-meter facility includes multiple 250L, 500L and 1000L single-use bioreactors as well as sterile drug-product...
Waterdrop Inc. to Report Third Quarter 2022 Financial Results on December 6, 2022
BEIJING, Dec. 2, 2022 /PRNewswire/ -- Waterdrop Inc. (NYSE: WDH) ("Waterdrop" or the "Company"), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2022, before U.S. markets open on Tuesday, December 6, 2022. Waterdrop's management team...
Japanese Healthcare Startup Ubie, Inc. Closes Extended Series C Round at $45 million, Establishes Subsidiary in NY
TOKYO, Dec. 8, 2022 /PRNewswire/ -- Ubie, Inc., a Tokyo-based healthcare startup, announced on December 8 that it has closed its Series C round at $45 million by raising $19 million in an extension round. The new funding will enable Ubie to accelerate its growth and strengthen its presence in the U.S., following strong interest and traction in that...
IND Application of Biosyngen’s Cell Therapy (BRG01) for Nasopharyngeal Cancer Approved by China NMPA
GUANGZHOU, China , Dec. 15, 2022 /PRNewswire/ -- On Dec. 14th, 2022, Guangzhou Biosyngen Co., Ltd. (hereinafter as "Biosyngen") made an announcement on the approval granted by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for the company's IND application for BRG01 Therapy. BRG01 Therapy is an autologous T cell therapy for relapsed/metastatic nasopharyngeal cancer...
